Opus Genetics (IRD) Stock Analysis & Winston Score

Opus Genetics is a small biotech company focused on developing gene therapies for rare inherited eye diseases that cause blindness. Its main programs target conditions like Best disease and other retinal dystrophies — genetic disorders where the eye's light-sensing cells slowly break down. The company's treatments are designed to deliver working copies of faulty genes directly into patients' eyes, potentially slowing or stopping vision loss. Opus Genetics does not yet sell any approved products, so it earns almost no revenue — which explains its deeply negative operating margin. The company is based in the United States and funds its research through equity raises and partnerships rather than product sales. Its competitive position depends on being early in a niche area of gene therapy where few other companies are focused, but the biggest risk is that clinical trials could fail or take many years, and the company will need to keep raising cash to survive until it can bring a product to market.